Safety and Efficacy of Valsartan and Amlodipine Combined and Alone in Hypertensive Patients
Primary Purpose
Hypertension
Status
Completed
Phase
Phase 3
Locations
International
Study Type
Interventional
Intervention
valsartan+amlodipine combination
valsartan
amlodipine
Sponsored by

About this trial
This is an interventional treatment trial for Hypertension focused on measuring HYPERTENSION, VALSARTAN, AMLODIPINE, high blood pressure
Eligibility Criteria
Inclusion Criteria:
- Outpatients 18 years and older.
- Male or female patients are eligible. Female patients must be either post-menopausal for one year or surgically sterile, or using effective contraceptive methods such as barrier method with spermicide or an intra-uterine device. Hormonal contraceptive use is disallowed.
- Patients with essential diastolic hypertension measured by calibrated standard aneroid or mercury (preferable) sphygmomanometer. Patients must have a MSDBP > 90 mmHg and < 110 mmHg at Visit 1 (week -4 to -2), and a MSDBP > 95 mmHg and < 110 mmHg at Visit 2 (week 0).
- Patients must have an absolute difference of > 10 mmHg in their average sitting diastolic blood pressure between Visits 1 and 2.
- Patients who are eligible and able to participate in the study, and who consent to do so after the purpose and nature of the investigation has been clearly explained to them (written informed consent).
Exclusion Criteria:
- Severe hypertension (MSDBP 110 mmHg and/or MSSBP 180 mmHg) at anytime.
- Inability to discontinue all prior antihypertensive medications safely for a period of 14 weeks.
- Known Keith-Wagener grade III or IV hypertensive retinopathy.
- History of hypertensive encephalopathy or cerebrovascular accident at anytime prior to Visit 0 (week -6 to -4).
- Transient ischemic cerebral attack during the last 12 months prior to Visit 0 (week -6 to -4).
- Evidence of a secondary form of hypertension, such as coarctation of the aorta, hyperaldosteronism, unilateral or bilateral renal artery stenosis, Cushing Disease, pheochromocytoma, polycystic kidney disease etc.
- Type 1 diabetes mellitus.
- Type 2 diabetes mellitus with poor glucose control as defined by fasting glycosylated hemoglobin (HbA1c) >8% at Visit 1 (week -4 to -2).
- Administration of any agent indicated for the treatment of hypertension within a minimum 4 weeks prior to randomization into the study (Visit 2, week 0), with the permitted exception of those anti-hypertensive medications requiring tapering down commencing at Visit 0 (week -6 to -4).
- Known or suspected contraindications, including history of allergy to angiotensin receptor blockers or calcium channel blockers.
- Other protocol-defined inclusion/exclusion criteria may apply
Sites / Locations
- Novartis Pharmaceuticals
- Sites in Germany
Outcomes
Primary Outcome Measures
Change from baseline (Visit 2) in mean sitting diastolic blood pressure at trough (endpoint-Week 8).
Secondary Outcome Measures
Change from baseline (Visit 2) in mean sitting systolic blood pressure at trough (endpoint-Wk 8)
Change from baseline (Visit 2) in standing diastolic and systolic blood pressure at trough(endpoint-Wk 8)
Sitting and standing pulse
Full Information
1. Study Identification
Unique Protocol Identification Number
NCT00409643
Brief Title
Safety and Efficacy of Valsartan and Amlodipine Combined and Alone in Hypertensive Patients
Official Title
A Randomized, Double-blind, Multicenter, Multifactorial, Placebo-controlled, Parallel Group Study to Evaluate the Efficacy and Safety of Valsartan (160 mg and 320 mg) and Amlodipine (10 mg) Combined and Alone in Hypertensive Patients
Study Type
Interventional
2. Study Status
Record Verification Date
November 2011
Overall Recruitment Status
Completed
Study Start Date
January 2004 (undefined)
Primary Completion Date
July 2004 (Actual)
Study Completion Date
July 2004 (Actual)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Novartis
4. Oversight
5. Study Description
Brief Summary
This trial will compare valsartan and amlodipine combination therapies to valsartan and amlodipine monotherapy,and placebo for treating patients with hypertension
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Hypertension
Keywords
HYPERTENSION, VALSARTAN, AMLODIPINE, high blood pressure
7. Study Design
Primary Purpose
Treatment
Study Phase
Phase 3
Interventional Study Model
Parallel Assignment
Masking
Double
Allocation
Randomized
Enrollment
1259 (Actual)
8. Arms, Groups, and Interventions
Intervention Type
Drug
Intervention Name(s)
valsartan+amlodipine combination
Intervention Type
Drug
Intervention Name(s)
valsartan
Intervention Type
Drug
Intervention Name(s)
amlodipine
Primary Outcome Measure Information:
Title
Change from baseline (Visit 2) in mean sitting diastolic blood pressure at trough (endpoint-Week 8).
Secondary Outcome Measure Information:
Title
Change from baseline (Visit 2) in mean sitting systolic blood pressure at trough (endpoint-Wk 8)
Title
Change from baseline (Visit 2) in standing diastolic and systolic blood pressure at trough(endpoint-Wk 8)
Title
Sitting and standing pulse
10. Eligibility
Sex
All
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria:
Outpatients 18 years and older.
Male or female patients are eligible. Female patients must be either post-menopausal for one year or surgically sterile, or using effective contraceptive methods such as barrier method with spermicide or an intra-uterine device. Hormonal contraceptive use is disallowed.
Patients with essential diastolic hypertension measured by calibrated standard aneroid or mercury (preferable) sphygmomanometer. Patients must have a MSDBP > 90 mmHg and < 110 mmHg at Visit 1 (week -4 to -2), and a MSDBP > 95 mmHg and < 110 mmHg at Visit 2 (week 0).
Patients must have an absolute difference of > 10 mmHg in their average sitting diastolic blood pressure between Visits 1 and 2.
Patients who are eligible and able to participate in the study, and who consent to do so after the purpose and nature of the investigation has been clearly explained to them (written informed consent).
Exclusion Criteria:
Severe hypertension (MSDBP 110 mmHg and/or MSSBP 180 mmHg) at anytime.
Inability to discontinue all prior antihypertensive medications safely for a period of 14 weeks.
Known Keith-Wagener grade III or IV hypertensive retinopathy.
History of hypertensive encephalopathy or cerebrovascular accident at anytime prior to Visit 0 (week -6 to -4).
Transient ischemic cerebral attack during the last 12 months prior to Visit 0 (week -6 to -4).
Evidence of a secondary form of hypertension, such as coarctation of the aorta, hyperaldosteronism, unilateral or bilateral renal artery stenosis, Cushing Disease, pheochromocytoma, polycystic kidney disease etc.
Type 1 diabetes mellitus.
Type 2 diabetes mellitus with poor glucose control as defined by fasting glycosylated hemoglobin (HbA1c) >8% at Visit 1 (week -4 to -2).
Administration of any agent indicated for the treatment of hypertension within a minimum 4 weeks prior to randomization into the study (Visit 2, week 0), with the permitted exception of those anti-hypertensive medications requiring tapering down commencing at Visit 0 (week -6 to -4).
Known or suspected contraindications, including history of allergy to angiotensin receptor blockers or calcium channel blockers.
Other protocol-defined inclusion/exclusion criteria may apply
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Novartis pharmaceuticals
Organizational Affiliation
Sponsor GmbH
Official's Role
Study Chair
Facility Information:
Facility Name
Novartis Pharmaceuticals
City
East Hanover
State/Province
New Jersey
ZIP/Postal Code
07936
Country
United States
Facility Name
Sites in Germany
City
Germany
Country
Germany
12. IPD Sharing Statement
Learn more about this trial
Safety and Efficacy of Valsartan and Amlodipine Combined and Alone in Hypertensive Patients
We'll reach out to this number within 24 hrs